(Press-News.org) A team of pediatricians at the Medical University of South Carolina (MUSC) was the first in the nation to enroll patients with multisystem inflammatory syndrome in children (MIS-C), a rare but life-threatening complication of COVID-19, in a trial of remestemcel-L. This investigational cell therapy, developed and manufactured by Mesoblast, New York, New York, had previously been shown safe and effective for other inflammatory conditions. The MUSC team reports in Pediatrics that the two children enrolled thus far showed significant improvement within 24 hours of remestemcel-L administration.
"While it appears to many people that COVID is no big deal in children, this potential complication, although rare, is very, very serious," said MUSC Children's Health pediatric infectious disease physician, Allison Eckard, M.D., who is leading the local trial. "In South Carolina, we have had over 70 cases of MIS-C and one death. That is way more than we'd like to see in children."
Too often, MIS-C is not recognized until children are already critically ill.
"The tricky part about MIS-C is that, in many cases, the families don't know that the children ever had COVID because, in general, children have very mild symptoms," said Eckard.
MIS-C can also be missed because its symptoms are vague, and so it can easily be mistaken for other illnesses.
Although the cause of MIS-C is unknown, Eckard speculates that the body's reaction to COVID-19 likely sets off a cascade of unchecked inflammation.
"Although inflammation has a role to play in the body, excessive inflammation is bad and causes organ damage, organ failure and a lot of other complications," she said.
The current standard of care for MIS-C is nonspecific. It consists of using steroids or antibodies derived from donated plasma to turn down all aspects of the immune system.
"The novel treatment we are using is a little bit more specific," said Eckard.
Remestemcel-L is a cellular therapy derived from a special type of cell that forms in bone marrow.
"These bone marrow cells, donated by healthy adults, are known to turn down inflammation," said Eckard. They are able to target the specific parts of the immune system that are most relevant to MIS-C.
The cells are also able to improve the inner lining of the blood vessel, targeting the most serious and potentially long-term effects of MIS-C: cardiac and cardiovascular involvement. Remestemcel-L improves blood pressure and the flow of blood to where it needs to be.
"We rely on the heart to pump blood adequately to all the other organs," said Eckard. "The same applies to blood vessels and the cardiovascular system. When they don't work properly, your body can't pump blood effectively to vital organs."
Nationwide studies have already been conducted on the use of remestemcel-L to treat graft-vs-host disease in children, a condition that can develop after receiving a bone marrow transplant, and MUSC participated in some of them. Other studies have also assessed its usefulness for treating cardiac complications in adults. However, MUSC is the only institution thus far to use remestemcel-L for the purpose of MIS-C.
"We always worry in pediatrics about the safety of new therapies. But because of our experience here at MUSC with hundreds of children enrolled in a remestemcel-L trial for graft-vs. host disease, we felt really good about its safety profile," said Eckard.
Thus far, two children have been enrolled in the trial and treated with remestemcel-L. They were chosen because they still had underlying inflammation and cardiac dysfunction despite having received standard-of-care therapy. Eckard hopes that the investigational therapy will help to protect these children from long-term cardiovascular complications.
"People are always very hesitant to try new things if they think the current therapy is working. But what I say to that is we do not know the long-term effects of MIS-C," said Eckard.
Although it is too early to know if the novel therapy will protect against long-term complications, Eckard is heartened by the therapy's short-term effects, which were reported in the Pediatrics article.
"There were some dramatic improvements within 24 hours of giving the treatment in both of the children, and that is what compelled us to publish those two cases," said Eckard.
The remestemcel-L trial for use in MIS-C aims to enroll 50 children with cardiac dysfunction nationwide. If the investigational treatment proves effective at treating MIS-C, it might also be studied in children with other inflammatory syndromes.
Future studies will aim to determine if the administration of remestemcel-L is alone responsible for the improvement of patients or if it still needs to be administered with plasma antibodies, which is the current but more expensive standard of care. The current standard-of-care therapies also have unwanted side effects that might be avoided if remestemcel-L is used instead.
"We want people to be more aware of the condition, but we also want to show people that we've had success with this therapy, in terms of safety and effectiveness, and encourage others to consider using it at their own institutions," said Eckard.
INFORMATION:
Disclosure: One of the article's authors is a consultant to Mesoblast and another is an employee. None of the other authors has conflicts of interest to disclose.
About MUSC
Founded in 1824 in Charleston, MUSC is the oldest medical school in the South as well as the state's only integrated academic health sciences center with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. The state's leader in obtaining biomedical research funds, in fiscal year 2019, MUSC set a new high, bringing in more than $284 million. For information on academic programs, visit musc.edu.
As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians' practice plan and nearly 325 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2020, for the sixth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.
MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.
During the COVID-19 pandemic, people who recognize the connections they share with others are more likely to wear a mask, follow health guidelines and help people, even at a potential cost to themselves, a new University of Washington study shows.
Indeed, an identification with all humanity, as opposed to identification with a geographic area like a country or town, predicts whether someone will engage in "prosocial" behaviors particular to the pandemic, such as donating their own masks to a hospital or coming to the aid of a sick person.
The study, published March 10 in PLOS ONE, is drawn from about 2,500 responses, from more than 80 countries, to an online, international ...
Images
As far back as the Greek historian Herodotus, a group of people called the Scythians were considered highly mobile warrior nomads.
Scythian-era people lived across Eurasia from about 700 BCE to 200 BCE, and have long been considered highly mobile warriors who ranged widely across the steppe grasslands. Herodotus describes Scythian populations as living in wagons and engaging in raiding and warfare, and this view has persisted throughout history--supported by archeologists' observations of similar styles of horse harnesses, weapons, burial mounds and animal style motifs throughout ...
A study conducted by researchers at the University of São Paulo in Brazil shows that competition for nutrients and lack of cooperation among bacteria of the species Escherichia coli in the same population and in situations of food scarcity prevent mutants that are better adapted to the environment from flourishing, except those that organize in small groups. The phenomenon masks the emergence of novel bacterial variants, making the mutation rate seem lower than it is in fact.
Mutants constantly emerge and accumulate from one generation to the next. Mutation frequency determines the evolution of a given species. Understanding ...
The legalization of cannabis and the arrival of nonmedical fentanyl are fundamentally changing drug markets in North America. A large part of these changes relates to the ability to produce large quantities of the drugs at low costs, which has slashed wholesale prices for both drugs and retail prices for cannabis. A new analysis explores the effects of these changes on use. The analysis concludes that sharp declines in production costs for cannabis and opioids could dramatically reduce the price per dose for consumers in ways that alter patterns of use and dependence.
The analysis, by a researcher at Carnegie Mellon University (CMU), is published in the International Journal of Drug Policy.
"Historical analogies suggest that very large ...
On December 6, 2016, a high-energy particle called an electron antineutrino was hurtling through space at nearly the speed of light. Normally, the ghostly particle would zip right through the Earth as if it weren't even there.
But this particle just so happened to smash into an electron deep inside the South Pole's glacial ice. The collision created a new particle, known as the W- boson. That boson quickly decayed, creating a shower of secondary particles.
The whole thing played out in front of the watchful detectors of a massive telescope buried in the Antarctic ice, the IceCube Neutrino Observatory. This enabled IceCube ...
MAYWOOD, IL - A recent Loyola Medicine study found that reducing the standard dose of IV-administered ketamine in half is as effective as the larger, standard dose in reducing pain in adults.
Ketamine is known to provide pain relief comparable to opioid medications, which are highly addictive. In the recent study, appearing in the journal Academic Emergency Medicine, researchers studied 98 patients, ages 18 to 59, who presented to the emergency department with acute, moderate to severe pain. The patients were randomized prospectively to receive either 0.15 mg/kg of ketamine (low dose) or 0.30 mg/kg (high dose). Patients ...
Drug developed by Northwestern scientists
Fatal brain cancer has no current cure
Drug is revolutionary new class of drugs applicable to other neurological diseases
CHICAGO --- An early clinical trial in individuals with the deadly brain cancer, glioblastoma, showed an experimental spherical nucleic acid (SNA) drug developed by Northwestern University scientists was able to penetrate the blood-brain barrier and trigger the death of tumor cells.
This is the first time a nanotherapeutic has been shown to cross the blood-brain barrier when given through intravenous infusion and alter the genetic machinery of a tumor to cause cell death. The drug crossed the blood-brain barrier, ...
By analyzing more than a decade's worth of information on 55 crops, all dependent on pollinators, scientists have revealed that developed countries are particularly reliant on imported pollinator-dependent crops, while countries that export the majority of these crop types are major drivers of pollinator declines. Their assessment of the "virtual" exchange of pollinator services in the global food trade could help governments and agencies form new policies to preserve crop diversity and tackle biodiversity loss. In today's globalized world, human food consumption largely depends on the trade of crops and the intense use of resources such as water and land. Pollinators such as bees, ...
OSAKA, Japan - The hippocampus is the part of the brain that deals with information associated with spatial navigation and memory. For example, you are driving and despite the changing environment of different cars going at varying speeds, on and off ramps, distracting billboards, etc., you adjust your speed, glance only momentarily at the billboards, and navigate the roads in a smooth and timely manner. This is your hippocampus at work. It takes the input - a continuously changing environment - and helps turn it into the output - using memory of a road map to safely navigate your way. However, little is known about how information is distributed from the hippocampus to other brain regions that results in the output behaviour.
A research team led by Lecturer Takuma Kitanishi and Professor ...
Social distancing not only helped slow the spread of COVID-19 -- it also may have prevented the transmission of an outbreak of a rare polio-like syndrome, according to Princeton University researchers.
Though uncommon, acute flaccid myelitis (AFM) is a critical spinal condition that causes weakness in the limbs, seriously diminishes motor function, and can lead to lifelong disabilities. The syndrome was first reported in the United States in 2012 and has been coming back every two years, hinting it could strike again in 2020.
Using epidemiological surveillance tools, the researchers showed that an AFM outbreak was ...
